MAIA Biotechnology, Inc.
AMEX:MAIABiotechnology
+$0.05 today
- Market cap
- $80.28M
- Beta
- 0.24
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 2.25M
Average 0.78M
MAIA Interest Expense
Cost of servicing the company's debt during the period.
MAIA Biotechnology, Inc.AMEX: MAIA
Interest Expense · Q1 FY2026 · quarter ended Mar 2026
Interest expense remains negative
Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.
Context
- Interest expense increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Expense history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Interest Expense | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 57 | — |
| FY2023 | 2023-12-31 | 0 | -100.0% |
| FY2022 | 2022-12-31 | 6.97K | -99.2% |
| FY2021 | 2021-12-31 | 827.54K | — |
Interest Expense vs competitors
How MAIA compares with its peers on the latest reported figures
- MAIA's LTM Mar 2026 interest expense of $0 is the 3rd highest of the 7 companies compared; the peer median is $0.
- Its year-over-year change of -100.0% is the 3rd highest of 5, against a peer median of -81.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $6.75M | +7.8% | — | 25.4% | |
| LTM Mar 2026 | $545K | -63.4% | -20.0% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding MAIA) | $0 | -81.7% | -20.0% | 12.7% | |
Competitors are the stored peer set for MAIA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 3.45M | 8.93M | 11.11M | 10.01M | 14.55B |
| Selling, General & Admin | 4.29M | 6.14M | 9.07M | 6.95M | 9.72B |
| Operating Expenses | 7.79M | 16.18M | 20.18M | 16.96M | 24.27M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 0 |
| EBITDA | (11.75M) | (15.76M) | (19.77M) | (23.25M) | (22.4M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (7.79M) | (16.18M) | (20.18M) | (16.96M) | (24.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 2.01K | 1.87K | 27.63K | 318.37K | 313.95K |
| Interest Expense | 827.54K | 6.97K | 0 | 57 | 0 |
| Other Income / Expenses | (4.79M) | 406.92K | 409.48K | (6.3M) | 1.87M |
| Income Before Tax | (12.58M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (12.5M) | (15.77M) | (19.77M) | (23.25M) | (22.4M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| EPS (Diluted) | (1.18) | (1.70) | (1.49) | (1.05) | (0.70) |
| Weighted Avg Shares | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
| Weighted Avg Shares (Diluted) | 10.64M | 9.28M | 13.26M | 22.2M | 32.12M |
MAIA Biotechnology, Inc.
AMEX:MAIA
Intrinsic Alpha fair value
Locked
Current Price
$1.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.